Close Menu

NEW YORK (360Dx) – Deep Lens said today that it has closed a $14 million Series A round to further expand its artificial intelligence and platform product development activities. It will also use the financing to scale its service, sales, and marketing organizations to support demand and growth for its approach to clinical trial recruitment.

The Series A closing comes three months after Columbus, Ohio-based Deep Lens completed a venture capital-led seed equity round, bringing its funding to date to $17.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.